ANETUMAB RAVTANSINE (BAY-94-9343) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/ Collaborator
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant CancerNCT02751918IBayer
Phase I Study of Anetumab Ravtansine in Hepatic or Renal ImpairmentNCT02696642IBayer
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and ItraconazoleNCT02824042IBayer
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)NCT02610140IBayer
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid TumorsNCT02639091IBayer
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung AdenocarcinomaNCT02839681IINational Cancer Institute (NCI)
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced MalignanciesNCT02485119IBayer